TRASTUZUMAB DERUXTECAN
Manner of administration:Injection
Restriction
Indication: Metastatic (Stage IV) HER2 positive breast cancer
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 675 mg | # of repeats: 8 | DPMA: $17,832.62 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Enhertu
(trastuzumab deruxtecan 100 mg injection, 1 vial)
|
||||
Manner of administration:Injection
Restriction
Indication: Metastatic (Stage IV) HER2 positive breast cancer
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 675 mg | # of repeats: 8 | DPMA: $17,542.65 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Enhertu
(trastuzumab deruxtecan 100 mg injection, 1 vial)
|
||||
Manner of administration:Injection
Restriction
Indication: Unresectable and/or metastatic HER2-low breast cancer
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 675 mg | # of repeats: 8 | DPMA: $17,832.62 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Enhertu
(trastuzumab deruxtecan 100 mg injection, 1 vial)
|
||||
Manner of administration:Injection
Restriction
Indication: Unresectable and/or metastatic HER2-low breast cancer
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 675 mg | # of repeats: 8 | DPMA: $17,542.65 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Enhertu
(trastuzumab deruxtecan 100 mg injection, 1 vial)
|
||||